These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3920361)

  • 1. Strontium-89 therapy for the pain of osseous metastases.
    Silberstein EB; Williams C
    J Nucl Med; 1985 Apr; 26(4):345-8. PubMed ID: 3920361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [89Sr Therapy for pain relief in patients with bone metastases].
    Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
    Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effects of strontium-89 against osseous metastases of lung cancer: analysis of 126 cases].
    Zheng H; Luo RC; Fan YX
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1194-6. PubMed ID: 15485798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
    Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
    Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective use of strontium-89 in osseous metastases.
    Kuroda I
    Ann Nucl Med; 2012 Apr; 26(3):197-206. PubMed ID: 22160737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
    Ouyang W; Liu JH; Liu WY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.